MedTrace Logo

Hepatitis C Rimantadine and Antiviral Combination Therapy

NCT01413490 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2015-03-31

No results posted yet for this study

Summary

Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.

Conditions

  • Hepatitis C

Interventions

DRUG

rimantadine

12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin

Sponsors & Collaborators

Principal Investigators

  • mark aldersley, mbbs phd · national health service

  • lynsey corless, mbchb phd · national health service

  • stephen griffin, bsc phd · University of Leeds

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413490 on ClinicalTrials.gov